A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06412562 In Psychiatrically Stable Subjects With Schizophrenia

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06412562 In Psychiatrically Stable Subjects With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs PF 6412562 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Nov 2016 Status changed from recruiting to completed.
    • 09 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
    • 09 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top